ezh2 Antibody

What is EZH2 and why is it a significant target for antibody-based research?

EZH2 functions as the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), responsible for trimethylation of lysine 27 on histone H3 (H3K27me3). This epigenetic modification typically results in transcriptional repression of target genes. EZH2 is a 751-amino acid protein with a molecular weight of approximately 85-100 kDa, containing several functional domains including the highly conserved SET domain responsible for its methyltransferase activity .

The significance of EZH2 as a research target stems from its involvement in various biological processes including cell differentiation, cell cycle regulation, and maintenance of stem cell pluripotency. Importantly, EZH2 dysregulation has been implicated in multiple cancer types, making it both a biomarker and potential therapeutic target . Antibodies against EZH2 enable researchers to study its expression patterns, protein interactions, chromatin binding sites, and functional roles in normal and pathological conditions.

EZH2 overexpression has been documented in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma, and testis , highlighting its relevance in cancer research. Additionally, recent evidence demonstrates EZH2's role in regulating immune responses, particularly in modulating antigen presentation pathways .

How do different types of EZH2 antibodies compare in terms of applications and specificity?

EZH2 antibodies are available in several formats, each with distinct characteristics that make them suitable for specific applications:

The choice of antibody should be guided by the intended application. For instance, search results indicate that antibody #39901 is specifically validated for ChIP-Seq and CUT&RUN applications, requiring 5 μl and 1 μl per reaction, respectively . For Western blot applications, antibody AF7901 has been validated for detecting EZH2 at approximately 85 kDa .

When selecting an EZH2 antibody, researchers should consider several factors including the specific epitope recognized, species cross-reactivity, and validated applications. For example, AF4767 specifically targets the region from Gly512 to Ile645 of human EZH2 , while other antibodies may target different regions that could affect their utility in various applications.

What are the optimal protocols for using EZH2 antibodies in Western blot applications?

Western blot analysis using EZH2 antibodies requires careful optimization to achieve specific and robust detection. Based on the provided search results, the following methodological considerations are crucial:

Sample Preparation:

• Prepare lysates from cell lines or tissue samples under reducing conditions

• For cell lines, HeLa, Jurkat, and Caco-2 have been successfully used to detect EZH2

• For tissue samples, mouse spleen tissue has shown good results

• Load approximately 10 μg of protein per lane for optimal detection

Antibody Conditions:

• For AF4767 (Goat Anti-Human/Mouse EZH2), use at a concentration of 1 μg/mL

• For AF7901 (Rabbit polyclonal), optimal dilutions should be determined empirically for each application

• Use appropriate HRP-conjugated secondary antibodies (e.g., Anti-Goat IgG for AF4767)

Detection Parameters:

• EZH2 typically appears as a band at approximately 80-85 kDa

• Include appropriate loading controls such as alpha-tubulin

• For comparison studies (e.g., knockdown experiments), include multiple biological replicates for statistical validity

Specialized Conditions:

• Use of Immunoblot Buffer Group 8 has been reported for successful detection with AF4767

• PVDF membrane is recommended for optimal protein transfer and antibody binding

It's important to note that knockdown or knockout controls significantly enhance the validity of Western blot results. The search results describe SIRT1 knockdown experiments in Caco-2 cells where EZH2 protein levels were successfully analyzed using anti-EZH2 antibodies .

How can EZH2 antibodies be effectively used in ChIP and ChIP-Seq experiments?

Chromatin immunoprecipitation (ChIP) and ChIP-Seq are powerful techniques for studying EZH2's genomic binding sites and associated histone modifications. The search results provide specific guidance for these applications:

Antibody Selection and Amount:

• For ChIP-Seq applications, 5 μl of antibody #39901 per reaction is recommended

• For the related CUT&RUN technique, a reduced amount of 1 μl per 50 μl reaction is sufficient

Experimental Design Considerations:

• Include appropriate controls such as IgG negative controls and positive controls targeting known EZH2-bound regions

• For studies investigating H3K27me3 (the histone mark deposited by EZH2), parallel ChIP experiments with H3K27me3-specific antibodies can provide complementary data

Data Analysis Approaches:

• ChIP-Seq data can reveal genome-wide EZH2 binding patterns and correlate with H3K27me3 enrichment

• Analysis of EZH2 binding at specific gene promoters, such as the β-2-microglobulin promoter mentioned in the search results, can provide insights into gene regulation mechanisms

The search results indicate that EZH2 inhibition reduces H3K27me3 modification on specific gene promoters, which can be effectively detected using ChIP approaches . This highlights the utility of combining ChIP experiments with pharmacological or genetic manipulation of EZH2 to understand its functional roles.

What are the key considerations when using EZH2 antibodies for immunofluorescence and immunohistochemistry?

Immunofluorescence (IF) and immunohistochemistry (IHC) are valuable techniques for visualizing EZH2 expression and localization in cells and tissues. Based on the search results and established protocols, the following considerations are important:

Sample Preparation:

• For FFPE (formalin-fixed paraffin-embedded) tissues, antigen retrieval is critical to expose epitopes masked during fixation

• For frozen sections, fixation conditions should be optimized to preserve both tissue morphology and antigen integrity

• Cell samples for IF should be fixed with paraformaldehyde (typically 4%) and permeabilized to allow antibody access to nuclear EZH2

Multiplexed Analysis:

• Advanced platforms like the Lunaphore COMET mentioned in the search results enable high-plex immunofluorescence with multiple antibodies simultaneously

• When analyzing EZH2 alongside other markers, careful selection of compatible secondary antibodies is essential to avoid cross-reactivity

Signal Detection and Quantification:

• EZH2 typically shows nuclear localization, so co-staining with DAPI or other nuclear markers is recommended

• For quantitative analysis, consistent imaging parameters and objective quantification methods should be applied

• Digital image analysis can help quantify parameters such as percentage of positive cells and staining intensity

The search results describe a sophisticated high-plex immunofluorescence approach using 22 antibodies to analyze various markers including immune-oncology, lymphoid, myeloid, epithelial, and stromal markers in the context of EZH2 inhibition . This demonstrates the potential for combining EZH2 analysis with comprehensive tissue profiling.

How can EZH2 antibodies be used to investigate the role of EZH2 in antigen presentation and cancer immunotherapy?

EZH2 has emerged as a regulator of antigen presentation pathways, with significant implications for cancer immunotherapy. The search results provide valuable insights into this research area:

Experimental Approaches:

• EZH2 inhibition using small molecules like GSK126 and EPZ6438 can be combined with antibody-based detection of MHC class I expression

• Flow cytometry with appropriate antibodies can quantify changes in surface expression of antigen presentation machinery components

• EZH2 antibodies can be used in chromatin immunoprecipitation assays to investigate direct regulation of genes involved in antigen presentation, such as β-2-microglobulin

Functional Assays:

• Antigen-specific CD8+ T-cell proliferation assays can assess the functional impact of EZH2 modulation

• IFNγ production and tumor cell cytotoxicity assays provide readouts of enhanced immune recognition

• Combined analysis of EZH2 expression and immune cell infiltration in tissue sections can reveal correlations between EZH2 activity and immune suppression

The search results describe how EZH2 inhibition enhances antigen presentation and sensitizes resistant tumors to anti-PD-1 therapy . Researchers found that EZH2 expression negatively correlates with antigen-processing machinery components in head and neck squamous cell carcinoma (HNSCC), and EZH2 inhibition significantly upregulates MHC class I expression . These findings suggest that combining EZH2 targeting with anti-PD-1 therapy may increase therapeutic efficacy in HNSCC and potentially other cancer types.

What techniques can be used to study EZH2-mediated epigenetic modifications and their functional consequences?

Understanding the epigenetic modifications mediated by EZH2 and their functional impacts requires integrated approaches combining antibody-based detection with functional assays:

Chromatin Modification Analysis:

• ChIP assays using antibodies against EZH2 and H3K27me3 can map genome-wide distribution patterns

• Sequential ChIP (re-ChIP) can determine co-occupancy of EZH2 with other epigenetic regulators

• CUT&RUN, for which antibody #39901 is validated , offers higher resolution mapping of chromatin associations

Transcriptional Impact Assessment:

• RNA-Seq following EZH2 inhibition or knockdown reveals genes under EZH2-mediated repression

• Integration of ChIP-Seq and RNA-Seq data can identify direct EZH2 target genes

• The search results describe RNA-Seq analysis revealing that EZH2 inhibition increases expression of immune regulatory pathways

Functional Validation:

• CRISPR-Cas9-mediated EZH2 deficiency, as described in the search results , provides a genetic approach to validate findings from pharmacological inhibition

• Lentiviral shRNA against EZH2, as mentioned in the search results , offers an alternative approach for EZH2 knockdown

• Correlation of H3K27me3 levels with gene expression changes confirms the functional significance of the epigenetic modifications

The search results describe how EZH2 inhibition decreased H3K27 methylation and increased promoter activation , supporting the mechanistic link between EZH2 activity, histone modification, and gene regulation. Single-cell RNA-Seq analysis following EZH2 inhibition revealed increases in immune cell populations and decreased abundance of epithelial cells , demonstrating the power of combining epigenetic modulation with comprehensive transcriptomic analysis.

What are common challenges when working with EZH2 antibodies and how can they be addressed?

Researchers often encounter technical challenges when working with EZH2 antibodies. Based on the search results and general antibody principles, here are common issues and their solutions:

Non-specific Binding:

• Challenge: Detection of multiple bands in Western blot or non-specific staining in IHC/IF

• Solution: Optimize antibody dilution, increase blocking stringency, and validate specificity using EZH2 knockout or knockdown controls as described in the search results

Variable Results Between Experiments:

• Challenge: Inconsistent detection of EZH2 across different experiments

• Solution: Standardize protocols, use recombinant antibodies for better consistency, and include positive controls in each experiment

Epitope Masking:

• Challenge: Reduced sensitivity in fixed tissues or certain sample preparations

• Solution: Optimize antigen retrieval methods and consider antibodies targeting different EZH2 epitopes

Species Cross-Reactivity Issues:

• Challenge: Unexpected cross-reactivity or lack of reactivity in certain species

• Solution: Select antibodies validated for the species of interest; the search results indicate options with reactivity to human, mouse, and rat EZH2

Application-Specific Optimization:

• Challenge: An antibody that works for Western blot may not work for IHC or ChIP

• Solution: Choose antibodies specifically validated for the intended application, as indicated in the search results (e.g., antibody #39901 for ChIP-Seq and CUT&RUN)

A valuable approach to address specificity concerns is to use multiple antibodies targeting different epitopes of EZH2 and compare results. Additionally, including proper controls such as SIRT1 knockdown experiments described in the search results can significantly enhance confidence in antibody specificity.

How should researchers interpret discrepancies in results between different EZH2 antibodies or detection methods?

Discrepancies in results obtained with different EZH2 antibodies are not uncommon and require careful interpretation:

Possible Causes of Discrepancies:

• Different antibodies may recognize distinct epitopes that could be differentially accessible in various experimental contexts

• Post-translational modifications of EZH2 might affect epitope recognition by certain antibodies

• EZH2 exists in different protein complexes, and antibodies might have varying abilities to detect complex-bound EZH2

• Some antibodies might cross-react with the related EZH1 protein due to sequence homology

Systematic Approach to Resolution:

• Compare the epitope specificity of the antibodies in question

• Validate results using genetic approaches (siRNA, shRNA, or CRISPR) as demonstrated in the search results

• Consider the specific application context - some antibodies perform better in certain applications

• Assess whether the discrepancy might reflect an actual biological difference rather than a technical artifact

Complementary Methods:

• Combine antibody-based detection with mRNA expression analysis

• Use mass spectrometry-based proteomics as an antibody-independent approach

• The search results describe the use of Western blotting to confirm EZH2 knockdown efficiency in conjunction with other techniques

The search results demonstrate how researchers validate findings through multiple approaches, such as combining pharmacological inhibition with genetic knockdown of EZH2 , which provides greater confidence in the observed biological effects.

How are EZH2 antibodies being utilized in single-cell and spatial transcriptomics research?

The integration of EZH2 research with advanced single-cell and spatial technologies represents a frontier in epigenetic research:

Single-Cell Applications:

• The search results describe single-cell RNA-Seq analysis following EZH2 inhibition, revealing cell type-specific responses

• EZH2 antibodies can be used in single-cell CUT&TAG approaches to map EZH2 binding or H3K27me3 at single-cell resolution

• Proximity ligation assays (PLA), mentioned as a published application for EZH2 antibodies , can detect protein-protein interactions at the single-cell level

Spatial Transcriptomics Integration:

• Combining EZH2 immunohistochemistry with spatial transcriptomics can reveal relationships between EZH2 expression and local gene expression patterns

• The search results mention high-plex immunofluorescence using the Lunaphore COMET platform with 22 antibodies , demonstrating the potential for spatial analysis of EZH2 in relation to multiple cell types and states

Technical Considerations:

• For single-cell applications, antibody specificity becomes even more critical due to the limited material available from individual cells

• Optimization of fixation and permeabilization conditions is essential for maintaining both cellular morphology and antibody accessibility

The UMAP analysis of single-cell RNA-Seq data described in the search results demonstrated enrichment of immune cell populations and decreased abundance of epithelial cells following EZH2 inhibition . This illustrates how single-cell approaches can reveal cell type-specific effects of EZH2 modulation that might be masked in bulk analysis.

What are the latest approaches for studying EZH2 in combination with immune checkpoint inhibitors?

The emerging role of EZH2 in regulating antigen presentation and immune responses has sparked interest in combining EZH2 targeting with immunotherapy approaches:

Preclinical Models:

• The search results describe using EZH2 inhibitors (GSK126 and EPZ6438) in human and mouse HNSCC cell lines to study effects on antigen presentation

• In vivo models combining EZH2 inhibition (using GSK503) with anti-PD-1 blocking antibodies have demonstrated the potential to overcome anti-PD-1 resistance

Mechanistic Investigations:

• EZH2 antibodies are essential tools for studying how EZH2 targeting affects the tumor microenvironment

• Multiplex immunofluorescence approaches, as described in the search results , enable comprehensive analysis of immune cell infiltration and activation states following EZH2 inhibition

Translational Considerations:

• Correlation of EZH2 expression with response to immune checkpoint inhibitors in patient samples

• Development of biomarkers to identify patients who might benefit from combined EZH2 and immune checkpoint targeting

The search results provide compelling evidence that targeting EZH2 enhances antigen presentation and can circumvent anti-PD-1 resistance . Specifically, EZH2 inhibition resulted in significant upregulation of MHC class I expression in HNSCC lines both in vitro and in vivo, enhancing antigen-specific CD8+ T-cell proliferation, IFNγ production, and tumor cell cytotoxicity .